Mucopolysaccharidosis Type I Market to Witness Upsurge in Growth at a CAGR of 8% During the Forecast Period (2025-2034) | DelveInsight

The future of MPS I treatment is poised for significant advancements, driven by ongoing research and innovative therapies. Emerging therapies, such as stem cell gene therapy, IDUA Gene therapy, and Recombinant DNA, including OTL-203, Lepunafusp alfa (JR-171), RGX-111, and Iduronicrin…